September 5, 2018
Preliminary Data from Groundbreaking Genome Editing Clinical Trial Encouraging
As part of the phase 1 clinical trial for patients with Hunter syndrome, Joseph Muenzer, MD, PhD, performed the UNC Clinical Translational and Research Center’s first-ever in vivo genome editing therapy, achieving a milestone in his own career.